DIN 02542250 — RANOPTO 10 MG
RANOPTO is a solution of Ranibizumab marketed by TEVA CANADA LIMITED. The full Ranibizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02542250
- Brand name
- RANOPTO
- Active ingredient
- Ranibizumab
- Strength
- 10 MG
- Dosage form
- SOLUTION
- Route
- INTRAVITREAL
- Manufacturer
- TEVA CANADA LIMITED
- Health Canada status
- MARKETED
- Drug class
- Anti-VEGF-A (vascular endothelial growth factor inhibitor) biologic
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Ranibizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02296810 | LUCENTIS | 10 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02425629 | LUCENTIS | 10 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02525852 | MELVIZO | 10 MG | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED |